Canadian investment bank AltaCorp Capital has published a research report explaining options for producing cannabinoids from sources beyond cannabis. Analyst and Managing Director David Kideckel, PhD, explained in “Synthetically-Derived Cannabinoids: The Next Generation of Cannabinoid Production” that synthetic and biosynthetic cannabinoid production have the potential to disrupt the cannabis industry supply chain. He details the benefits and disadvantages to these alternative production processes relative to plant-based extraction:
Kideckel expects that biosynthetic production could play an important role in creating cannabinoids for consumer and pharmaceutical products, though he doesn’t see synthetic methods entirely replacing plant-derived extraction, noting that it could be at least 18 months before they are commercially feasible. The report also lists several companies involved in these types of alternative production, some of which are publicly-traded.
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email